The Use of Transcranial Magnetic Stimulation in the Treatment of Depressive Disorder in Parkinson’s Disease

被引：0

作者：

Prosvetov A.O. ^{[1
]}

Tsygankov B.D. ^{[1
]}

Guekht A.B. ^{[2
]}

Kuznetsov E.V. ^{[1
]}

Less U.E. ^{[2
]}

Tumurov D.A. ^{[2
]}

Popov G.R. ^{[2
]}

Tsygankov D.B. ^{[3
]}

Rangus S.R. ^{[1
]}

机构：

[1] Evdokimov Moscow State Medical and Dental University, Russian Ministry of Health, Moscow

[2] Solov’ev Scientific and Applied Psychoneurology Center, Moscow Health Department, Moscow

[3] Institute of Metal Health and Addiction Medicine, Moscow

来源：

Neuroscience and Behavioral Physiology | 2023年 / 53卷 / 4期

关键词：

affective disorders; depressive disorder; Parkinson’s disease; therapy; transcranial magnetic stimulation;

D O I：

10.1007/s11055-023-01450-4

中图分类号：

学科分类号：

摘要：

The prevalence of affective disorders in patients with Parkinson’s disease (PD) is significantly higher than that in the general population of people of the same age. The efficacy of antidepressants in PD with depressive disorder is known to be lower than in patients with primary depression. Other therapeutic strategies are available in cases of depression refractory to standard pharmacotherapy. Transcranial magnetic stimulation is one of the most popular and safe methods of brain stimulation and has been used with success to treat primary depression. The accumulation of experience in the use of transcranial magnetic stimulation has allowed the application of this method to be expanded to other nosologies, including PD. This article reflects published data on the use of different transcranial magnetic stimulation protocols for the treatment of depressive disorder in patients with PD. © 2023, Springer Nature Switzerland AG.

引用

页码：517 / 523

页数：6

共 47 条

[1]

Tysnes O., Storstein A., Epidemiology of Parkinson’s disease, J. Neural Transm. (Vienna), 124, 8, pp. 901-905, (2017)

[2]

Parkinson J., An Essay on Shaking Palsy, (1817)

[3]

Randver R., Repetitive transcranial magnetic stimulation of the dorsolateral prefrontal cortex to alleviate depression and cognitive impairment associated with Parkinson’s disease: A review and clinical implications, J. Neurol. Sci., 393, pp. 88-99, (2018)

[4]

von Campenhausen S., Bornschein B., Wick R., Et al., Prevalence and incidence of Parkinson’s disease in Europe, Eur. Neuropsychopharmacol., 15, 4, pp. 473-490, (2005)

[5]

de Rijk M.C., Breteler M.M., Graveland G.A., Et al., Prevalence of Parkinson’s disease in the elderly: The Rotterdam Study, Neurology, 45, 12, pp. 2143-2146, (1995)

[6]

de Lau L.M., Breteler M.M., Epidemiology of Parkinson’s disease, Lancet Neurol., 5, 6, pp. 525-535, (2006)

[7]

Simon D.K., Tanner C.M., Brundin P., Parkinson disease epidemiology, pathology, genetics, and pathophysiology, Clin. Geriatr. Med., 36, 1, pp. 1-12, (2020)

[8]

Sung V.W., Nicholas A.P., Nonmotor symptoms in Parkinson’s disease: Expanding the view of Parkinson’s disease beyond a pure motor, pure dopaminergic problem, Neurol. Clin., 31, 3, pp. S1-S16, (2013)

[9]

Chaudhuri K.R., Yates L., Martinez-Martin P., The non-motor symptom complex of Parkinson’s disease: A comprehensive assessment is essential, Curr. Neurol. Neurosci. Rep., 5, 4, pp. 275-283, (2005)

[10]

Shulman L.M., Taback R.L., Bean J., Weiner W.J., Comorbidity of the nonmotor symptoms of Parkinson’s disease, Mov. Disord., 16, 3, pp. 507-510, (2001)

← 1 2 3 4 5 →